NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

病毒載體及質體DNA實驗服務的全球市場:市場規模、佔有率、預測、機會分析 - 各實驗服務、終端用戶

Viral Vector and Plasmid DNA Testing Services Market: by Testing Services, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

出版商 Coherent Market Insights 商品編碼 931876
出版日期 內容資訊 英文 145 Pages
商品交期: 2-3個工作天內
價格
病毒載體及質體DNA實驗服務的全球市場:市場規模、佔有率、預測、機會分析 - 各實驗服務、終端用戶 Viral Vector and Plasmid DNA Testing Services Market: by Testing Services, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027
出版日期: 2020年03月12日內容資訊: 英文 145 Pages
簡介

由於病毒媒介是最適合基因治療的方法,適時開發以病毒載體為基礎的治療方法中,檢驗服務成為重要的要素。現在,病毒載體,用於市場認證的複數病毒為基礎的醫藥品,為了癌症、腫瘤,神經疾病,血液疾病,眼科疾病,代謝疾病,肌肉疾病等的各種治療而開發。以病毒為基礎的醫藥品,預期有許多革新,預期在醫藥品領域的未來性。病毒載體及質體DNA實驗服務市場,由於現在進行中使用病毒載體及質體DNA的各種治療藥的臨床試驗預計促進成長。

本報告提供全球病毒載體及質體DNA實驗服務市場調查,市場概要,各實驗服務、終端用戶、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 調查目的與假設

  • 調查目的
  • 假設
  • 簡稱

第2章 市場展望

  • 報告概要
    • 市場定義和範圍
  • 摘要整理
    • 市場片段:各實驗服務
    • 市場片段:各終端用戶
    • 市場片段:各地區
  • Coherent Opportunity Map(COM)

第3章 市場動態、規定、趨勢分析

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 主要的開發趨勢
  • 法規指南
  • 法規方案
  • 合併、收購
  • 產品上市
  • 流行病學
  • 開發平台分析
  • 新產品的上市
  • 已通過核准產品一覽
  • PEST分析

第4章 全球病毒載體及質體DNA實驗服務市場:各實驗服務

  • 簡介
  • 安全性
  • 遺傳特性
  • 純度
  • 鑑定
  • 效力

第5章 全球病毒載體及質體DNA實驗服務市場:各終端用戶

  • 研究機關
  • 製藥、生物科技企業

第6章 全球病毒載體及質體DNA實驗服務市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東
  • 非洲

第7章 競爭情形

  • 企業簡介
    • Charles River Laboratories, Inc.
    • WuXi AppTec Co., Ltd.
    • Cobra Biologics and Pharmaceutical Services
    • Merck KGaA
    • Lonza
    • Eurofins Scientific
    • FinVector Vision Therapies
    • Advanced Bioscience Laboratories, Inc.
    • TaKaRa BIO
    • ViruSure GmbH
    • Genezen Laboratories

第8章 Section

  • 參考資料
  • 調查手法
  • 關於Coherent Market Insights
目錄

Viral vectors are the best approach used in the gene therapies and therefore, testing services are the key factors for the timely development of viral vector-based therapies. Viral vector characterization plays an important role for orthogonal analytical approaches. The characterization is significant through the regulatory perspective, which include product safety, identity, purity, and potency. Nowadays, viral vector are the leading vehicle for the multiple virus-based drugs, which are approved in the global market and are developed for various treatments such as cancer and neurology, hematology, ophthalmology, and metabolic or muscular disorders. Viral-based products has the promising future in the pharmaceutical sector for many innovations.

The ongoing clinical trials on the viral vectors and plasmid DNA for various treatment is expected to fuel growth of the market in the forecast period. For instance, according to data published in the Journal of Gene Medicine, March 2018, till November 2017, around 2,600 gene therapy clinical trials were ongoing that are approved in 36 countries which include the U.S., the U.K., Australia, Canada, China, France, Germany, Japan, Switzerland, the Netherlands, and others. Moreover, diseases targeted by gene therapies include cardiovascular diseases, cancer, inflammatory and infectious diseases, Hemophilia A and B, severe combined immunodeficiency (SCID), ocular diseases, neurological diseases, and others.

Furthermore, favorable regulations imposed by the regulatory authorities for the specific utilization of viral vectors or plasmid DNA in the industries are expected to fuel growth of the market. For instance, in March 2018, the European Medicines Agency (EMA) drafted a guideline on the quality, non-clinical, and clinical aspects of gene therapy medicinal products, wherein the agency stated that characterization studies should be conducted throughout the development process right from starting materials, intermediates, drug substance and drug product in the gene therapy medicinal products (GTMP). The agency also stated that the characterization of the vector should include all components, but in particular, those present in the final product to be administered.

Market Dynamics

The viral vector and plasmid DNA testing services market is expected to witness significant growth over the forecast period, owing to rising number of business expansion by opening a new center or process development service (PDS). For instance, in February 2019, LakePharma, Inc., a contract research, development, and manufacturing organization (CRDMO), announced the availability of its vector center commercially located at Worcester, U.S. for offering broad range of services such as viral vector production, CAR-T engineering, analytical development of vectors, and others. The company also made lentivirus, adeno-associated virus (AAV), and baculovirus production systems available at the center.

Moreover, acquisitions by the major players are expected to drive growth of viral vector and plasmid DNA testing services market over the forecast period. For instance, in November 2018, ABL Europe SAS, a subsidiary of ABL, Inc., acquired a former Accinov GMP manufacturing site located in Lyon, France for expansion of viral vector GMP contract manufacturing capacity in the gene therapy space. The site has 3 GMP suites, laboratory and office, which provides process development, and analytical support for gene therapy.

Key features of the study:

This report provides in-depth analysis of the viral vector and plasmid DNA testing services market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2019 -2027), considering 2018 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global viral vector and plasmid DNA testing services market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans

Key companies covered as part of this study include Charles River Laboratories, Inc., WuXi AppTec Co., Ltd., Cobra Biologics and Pharmaceutical Services, Merck KGaA, Lonza, Eurofins Scientific, FinVector Vision Therapies, Advanced Bioscience Laboratories, Inc., Takara Bio Inc., ViruSure GmbH, and Genezen Laboratories amongst others

Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, technology upgradation, market expansion, and marketing tactics

The global viral vector and plasmid DNA testing services market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the viral vector and plasmid DNA testing services market

Detailed Segmentation:

  • Global viral vector and plasmid DNA testing services market, by testing services:
  • Safety
  • Genetic Characterization
  • Purity
  • Identity
  • Potency
  • Global viral vector and plasmid DNA testing services market, By end user:
  • Research Organizations
  • Pharmaceutical and Biotechnological Companies
  • Global viral vector and plasmid DNA testing services market, By Region:
  • North America
  • By Testing Services:
  • Safety
  • Genetic Characterization
  • Purity
  • Identity
  • Potency
  • By End User:
  • Research Organizations
  • Pharmaceutical and Biotechnological Companies
  • By Country:
  • U.S.
  • Canada
  • Latin America
  • By Testing Services:
  • Safety
  • Genetic Characterization
  • Purity
  • Identity
  • Potency
  • By End User:
  • Research Organizations
  • Pharmaceutical and Biotechnological Companies
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Testing Services:
  • Safety
  • Genetic Characterization
  • Purity
  • Identity
  • Potency
  • By End User:
  • Research Organizations
  • Pharmaceutical and Biotechnological Companies
  • By Country:
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Testing Services:
  • Safety
  • Genetic Characterization
  • Purity
  • Identity
  • Potency
  • By End User:
  • Research Organizations
  • Pharmaceutical and Biotechnological Companies
  • By Country:
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Pakistan
  • Rest of Asia Pacific
  • Middle East
  • By Testing Services:
  • Safety
  • Genetic Characterization
  • Purity
  • Identity
  • Potency
  • By End User:
  • Research Organizations
  • Pharmaceutical and Biotechnological Companies
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Testing Services:
  • Safety
  • Genetic Characterization
  • Purity
  • Identity
  • Potency
  • By End User:
  • Research Organizations
  • Pharmaceutical and Biotechnological Companies
  • By Country/Region:
  • North Africa
  • Central Africa
  • South Africa
  • Company Profiles
  • Charles River Laboratories, Inc.*
  • Company Highlights
  • Products Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
  • WuXi AppTec Co., Ltd.
  • Cobra Biologics and Pharmaceutical Services
  • Merck KGaA
  • Lonza
  • Eurofins Scientific
  • FinVector Vision Therapies
  • Advanced Bioscience Laboratories, Inc.
  • Takara Bio Inc.
  • ViruSure GmbH
  • Genezen Laboratories
  • "*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Testing Services
    • Market Snippet, By End User
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Key Developments
  • Regulatory Guidelines
  • Regulatory Scenario
  • Merger & Acquisitions
  • Product Launch
  • Epidemiology
  • Pipeline Analysis
  • New Product Launches
  • List of Approved Products
  • Pest Analysis

4. Global Viral Vector and Plasmid DNA Testing Services Market, By Testing Services, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Safety
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Genetic Characterization
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Purity
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Identity
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Potency
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

5. Global Viral Vector and Plasmid DNA Testing Services Market, By End User, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Research Organizations
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Pharmaceutical and Biotechnological Companies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

6. Global Viral Vector and Plasmid DNA Testing Services Market, By Region, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2016 and 2026 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2027
  • North America
    • Market Size and Forecast, By Testing Services, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Testing Services, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Testing Services, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Testing Services, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Pakistan
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Testing Services, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Testing Services, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

7. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • Charles River Laboratories, Inc.
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • WuXi AppTec Co., Ltd.
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • Cobra Biologics and Pharmaceutical Services
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • Merck KGaA
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • Lonza
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • Eurofins Scientific
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • FinVector Vision Therapies
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • Advanced Bioscience Laboratories, Inc.
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • Takara Bio Inc.
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • ViruSure GmbH
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
    • Genezen Laboratories
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Analyst Views

8. Section

  • References
  • Research Methodology
  • About Us and Sales Contact